Delcath Systems' (DCTH) "Buy" Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of Delcath Systems (NASDAQ:DCTH - Free Report) in a report released on Friday morning, Benzinga reports. They currently have a $21.00 price objective on the stock.

Other analysts have also issued research reports about the stock. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Delcath Systems in a research report on Friday. Craig Hallum initiated coverage on Delcath Systems in a report on Friday, June 28th. They set a "buy" rating and a $18.00 price objective on the stock. StockNews.com lowered Delcath Systems from a "hold" rating to a "sell" rating in a research note on Thursday. Finally, Stephens reissued an "overweight" rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Tuesday, August 6th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of "Moderate Buy" and an average price target of $21.50.

Delcath Systems Trading Up 10.3 %

Shares of DCTH stock traded up $1.05 during trading hours on Friday, hitting $11.28. The company's stock had a trading volume of 818,918 shares, compared to its average volume of 259,729. The business has a fifty day moving average of $9.12 and a 200-day moving average of $7.71. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $11.74. The stock has a market cap of $313.43 million, a price-to-earnings ratio of -4.26 and a beta of 0.78.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its earnings results on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.12). Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. The company had revenue of $7.77 million during the quarter, compared to analysts' expectations of $5.00 million. During the same period in the previous year, the company posted ($0.58) EPS. On average, equities analysts expect that Delcath Systems will post -1.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DCTH. Levin Capital Strategies L.P. grew its stake in Delcath Systems by 12.2% during the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company's stock worth $262,000 after buying an additional 5,969 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Delcath Systems during the 2nd quarter worth $370,000. Renaissance Technologies LLC acquired a new stake in Delcath Systems in the 2nd quarter valued at $694,000. Marshall Wace LLP raised its position in Delcath Systems by 7.0% in the second quarter. Marshall Wace LLP now owns 92,731 shares of the company's stock valued at $776,000 after purchasing an additional 6,066 shares during the period. Finally, Legato Capital Management LLC acquired a new position in shares of Delcath Systems during the second quarter worth about $966,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.